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Sleeping Beauty (SB) transposase enables somatic inte-
gration of exogenous DNA in mammalian cells, but 
potency as a gene transfer vector especially in large 
mammals has been lacking. Herein, we show that hyper-
active transposase system delivered by high-capacity 
adenoviral vectors (HC-AdVs) can result in somatic inte-
gration of a canine factor IX (cFIX) expression-cassette in 
canine liver, facilitating stabilized transgene expression 
and persistent haemostatic correction of canine hemo-
philia B with negligible toxicity. We observed stabilized 
cFIX expression levels during rapid cell cycling in mice 
and phenotypic correction of the bleeding diathesis in 
hemophilia B dogs for up to 960 days. In contrast, sys-
temic administration of an inactive transposase system 
resulted in rapid loss of transgene expression and tran-
sient phenotypic correction. Notably, in dogs a higher 
viral dose of the active SB transposase system resulted 
into transient phenotypic correction accompanied by 
transient increase of liver enzymes. Molecular analysis 
of liver samples revealed SB-mediated integration and 
provide evidence that transgene expression was derived 
mainly from integrated vector forms. Demonstrating 
that a viral vector system can deliver clinically relevant 
levels of a therapeutic protein in a large animal model 
of human disease paves a new path toward the possible 
cure of genetic diseases.
Received 2 February 2010; accepted 13 July 2010; published online  
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IntroductIon
Hemophilia B is an X-linked inherited blood clotting disorder 
caused by mutations in the coagulation factor IX (FIX) gene. This 
genetic disease has a prevalence of about 1 in 30,000 Caucasian 
males. Current standard therapies for hemophilia B are based 
on protein infusion treatments utilizing recombinant proteins or 
plasma-derived blood components. However, limitations of this 
treatment option are the potential development of inhibitors, the 
inconvenience of repeated injections of the coagulation factor 
concentrates, and the expenses of replacement factor production.
As an alternative treatment strategy for hemophilia B, a pleth-
ora of liver-based gene therapy approaches have been proposed. 
Preclinical studies in murine and canine models for hemophilia 
B involving gene delivery vehicles based on retrovirus, lenti virus, 
adeno-associated virus (AAV), and recombinant adenovirus were 
performed. Moloney murine leukemia virus-based retroviral 
vectors for example, which integrate into the host genome, were 
 utilized in hemophilia dogs.1 Furthermore, lentiviral vectors have 
been shown to be sufficient in mice but efficacy in hemophilia B 
dogs remains to be shown.2,3 To date the longest duration of canine 
FIX (cFIX) expression (8 years) in hemophilia B dogs was demon-
strated after a single liver-directed injection of a recombinant 
AAV based on serotype 2 vector (AAV2).4 In that particular study 
it is claimed that extrachromosomal AAV vector genomes were 
responsible for long-term expression of cFIX. Unfortunately, in the 
context of a clinical trial in hemophilia patients, this AAV-based 
approach resulted in transient phenotypic correction (2 months) 
of the bleeding diathesis5 most likely due to an adaptive immune 
response directed against the incoming viral capsid.
In the present study, we utilized an integrating adenoviral 
hybrid-vector system for somatic integration and long-term phe-
notypic correction of the bleeding disorder. Various generations 
of recombinant adenoviral vectors were used in the past for the 
treatment of hemophilia B. The early generation vectors deleted 
for the early-transcribed adenoviral genes E1 and E3 resulted in 
therapeutic cFIX levels in mice and hemophilia B dogs. However, 
cFIX levels in mouse serum although in a therapeutic range sig-
nificantly decreased over time and plasma cFIX levels of treated 
animals declined to undetectable levels 2 months postinjection.6 
It became clear that synthesized viral antigens expressed from 
the early generation recombinant adenoviral genomes induced 
immune responses that are at least in part responsible for destruc-
tion of transduced cells. The primary immune effector cells in this 
process are major histocompatibility complex class I-restricted 
cytotoxic T-lymphocytes.7–9 Further deletion of the E2a, E2b, or E4 
regions, while appearing safer, still resulted in some toxicity.10–12
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The newest generation of adenoviral vectors is deleted for 
all viral coding sequences allowing for packaging of up to 36 kb 
of foreign DNA.13,14 These vectors are commonly referred to as 
“ gutted,” gene-deleted, helper-dependent, or high-capacity adeno-
viral  vectors (HC-AdVs). It was demonstrated that hepatic trans-
duction utilizing HC-AdV is not accompanied by chronic toxicity 
due to the absence of viral gene expression.15,16 However, even 
HC-AdVs exhibit some dose-dependent toxicity related to the 
incoming viral particles (vps).17 It was shown that systemic cytok-
ines including the early indicator of inflammation interleukin-6 as 
mediators of the innate immune responses were activated17,18 and 
an attenuated adaptive immune response was observed due to an 
infiltration of adenovirus-specific cytotoxic T-lymphocytes.19
Nonetheless, none of the currently available gene transfer 
vehicles for gene therapeutic applications is flawless and, to date, 
HC-AdV still represents one of the most promising gene delivery 
vehicles. This type of vector has been shown to result in long-term 
transgene expression and phenotypic correction in various species 
and animal models. We and others have shown that after a single 
injection a HC-AdV can be maintained life-long in mice and for up 
to 2 years in rats.16,20–23 In dogs and nonhuman primates, HC-AdV 
liver transduction also led to long-term transgene expression.15,16 
To date, the longest period of transgene expression (up to 964 
days) was observed by Brunetti-Pierri and colleagues using a 
HC-AdV for hepatic transduction of baboons.16,24 With respect 
to canine hemophilia B, there are currently two studies utilizing 
HC-AdV based on human adenovirus serotype 5. Our previous 
study demon strated that, at a nontoxic dose, transient phenotypic 
correction can be achieved for several weeks after systemic admin-
istration of HC-AdV into hemophilia B dogs.25 Another study 
observed long-term phenotypic correction at a higher dose which 
in turn was associated with transient liver toxicity.26
With a very few exceptions (e.g., in embryonic stem cells)27 
adenoviral vectors are believed to integrate into host chromo-
somes at low frequencies.28,29 To prolong the therapeutic effect 
after liver-based adenoviral gene transfer and to stabilize persis-
tence of the therapeutic DNA at a lower dose, we hypothesized 
that somatic integration of the transgene from the episomal 
adeno viral vector genome into the host genome may stabilize and 
prolong the therapeutic effect. To test this hypothesis, we evalu-
ated an improved version of our previously described adenovirus/
Sleeping Beauty (SB) transposase hybrid-vector system30 for the 
first time in a canine model for hemophilia B. For high integration 
efficiencies into genomic DNA, the hybrid-vector technology uti-
lized in the present study was based on a hyperactive version of the 
SB transposase (HSB5). This transposable element was originally 
generated from inactive copies of an ancestral Tc1/mariner-like 
transposon in fish31 and the mechanism for SB-mediated somatic 
integration is schematically shown in Figure 1a. By performing 
a mutational analysis screen the hyperactive mutant HSB5 was 
identified displaying tenfold higher integration efficiencies com-
pared to wild-type SB.32 Herein, we show that this integrating viral 
vector system results in significantly stabilized transgene expres-
sion in rapidly dividing hepatocytes in mice. Furthermore, we 
demonstrate for the first time efficacy of a SB transposase system 
in a large  animal exemplified by long-term phenotypic correction 
in a canine model for hemophilia B.
results
A two-component system for transposon 
mobilization from Hc-AdVs
To achieve stabilized transgene expression, we used an improved 
version of the “two-vector-system” presented in our previous 
study.30 This system relies on cotransduction of one cell with 
two HC-AdVs. The first vector represents the transposon donor-
 vector (HC-AdV-TcFIX) which contains a transposon encoding 
the canine coagulation factor IX (cFIX)25 under the control of the 
liver-specific human α-1-antitrypsin promoter (hAAT) flanked by 
FRT recognition sites for Flp-mediated recombination (Figure 1b). 
The second vector (HC-AdV-HSB5) encodes Flp recombinase and 
the hyperactive SB transposase mutant HSB5 (Figure 1b), which 
displays tenfold increased integration efficiencies in comparison 
to the wild-type transposase.32 The mechanism of transposition 
from the adenoviral vector depends on two steps (Figure 1c). 
After both vectors cotransduce a target cell, Flp recombinase first 
mediates circularization of the transposon from the adenoviral 
vector genome. This step was necessary because adenoviral vec-
tor genomes predominantly exist as linear DNA molecule and we 
showed in the past that transposition mainly works from circular 
substrates.30 In a second step, the excised circle serves as a sub-
strate for SB transposase-mediated somatic integration.
As a negative control for the integration machinery a  derivate 
of the second vector (HC-AdV-mSB) containing an inactive 
version of SB transposase (mSB) was generated (Figure 1b). 
HC-AdVs were produced according to a previously described pro-
tocol for large-scale production of HC-AdV in spinner flasks.33,34 
Final vector preparations were analyzed for helper virus contami-
nation levels and the amount of transducing units per volume 
of the HC-AdV was determined (for details see Supplementary 
Materials and Methods section).
stable transgene expression in mice after a single 
injection of the adenovirus/sB transposase  
hybrid-vector system
To address the question whether the new version of the adeno-
viral hybrid-vector system results into stable transgene expression 
levels in vivo, C57Bl/6 mice were coinjected at a ratio of 3:1 with 
the vectors HC-AdV-TcFIX and HC-AdV-HSB5, respectively. As 
a negative control for HSB5-mediated somatic integration, mice 
were treated with HC-AdV-mSB instead of HC-AdV-HSB5. In two 
independent experiments, animals were injected with 3 × 1010 and 
1 × 1010 vps, respectively, or with a twofold higher dose. Animal 
injections, the viral dose, and the vector combinations, which were 
used, are summarized in Table 1. To demonstrate HSB5-mediated 
integration of the transgene expression-cassette from the adeno-
viral vector genome into the host chromosomal DNA, we intra-
peritoneally injected carbon tetrachloride (CCl4) 5–7 weeks after 
vector administration. CCl4 causes liver damage and therefore in 
treated liver tissue rapid cell cycling takes place to reconstitute nor-
mal liver size. As a consequence episomal  vector forms are lost due 
to cell division whereas integrated transposons are maintained. 
To analyze stability of canine FIX expression, cFIX serum levels 
were measured periodically by enzyme-linked immuno sorbent 
assay (ELISA) (Figure 2a). For mice treated with the functional 
SB transposase system, plasma cFIX levels maintained stable in a 
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physiological range (cFIX levels of 2,000–10,000 ng/ml) even after 
injection of CCl4, whereas in mice transduced with vector encod-
ing the inactive mSB, serum cFIX levels significantly dropped after 
CCl4 administration to concentrations <150 ng/ml (mice M2–M4) 
or undetectable levels (mice M7 and M8).
As additional control, we analyzed the expression from epi-
somal HC-AdV-TcFIX without Flp-mediated excision of the 
transposon. Therefore, mice were injected with the HC-AdV-
TcFIX and HC-AdV-luciferase (see also Supplementary Materials 
and Methods section), a HC-AdV encoding for firefly luciferase 
replacing the vector HC-AdV-HSB5 in our experimental setup. 
Before injection of CCl4 similar serum, cFIX levels were detected 
in both groups. However, after a single injection of the liver 
toxin CCl4 expression levels rapidly decreased within the next 
3 weeks (from serum cFIX levels of 1,300 to levels of 120 ng/ml) 
(Supplementary Figure S1). In sharp contrast, transgene expres-
sion levels from untreated mice remained stable.
To directly compare stability of transgene expression from 
episomal HC-AdV, HC-AdVs from which the transgene is 
excised, and HC-AdVs from which the transgene is excised and 
subsequently integrated into the host genome, we determined the 
loss rate of transgene expression for all systems with and without 
induction of rapid cell cycling in murine liver. We found that our 
integrating HC-AdV system utilizing HSB5 for somatic integra-
tion is superior in cycling cells compared to episomal HC-AdVs 
(Figure 2b). Moreover, we observed that the loss rate of transgene 
expression was independent of excision of the transposon from 
the adenoviral vector (Figure 2b). In conclusion, these results 
demonstrate that our system is clearly superior in rapidly dividing 
cells compared to conventionally used HC-AdVs, suggesting that 
this system may be useful for stable transduction of dividing cells 
(e.g., stem cells).
We also performed limited toxicity studies by monitoring ala-
nine aminotransferase (ALT) levels in mouse serum samples of 
treated mice to detect acute toxicity associated with administra-
tion of HC-AdVs. As a negative control, mice were injected with 
Dulbecco’s phosphate-buffered saline (PBS), the solvent for the 
HC-AdVs for injections. One day postinjection comparable ALT 
levels were measured in mice which received the HSB5 or the mSB 
vector system (Figure 2c). Although ALT levels in HSB5- and 
mSB-treated mice were slightly elevated compared to the control 
group treated with Dulbecco’s PBS, we would like to emphasize 
that ALT levels remained in the normal range for all treated mice 
(20–80 IU/l).
Phenotypic correction after intravenous injection 
of the adenovirus/sB tranposase hybrid-vector 
system into hemophilia B dogs
After verifying that this improved version of the transposase sys-
tem works efficiently in mice, we addressed the question whether 
transposition enables phenotypic correction in a preclinical 
 animal model for hemophilia B. Therefore, we intravenously 
injected three hemophilia B dogs carrying a missense mutation 
in the catalytic domain of the genomic cFIX coding sequence.35 
All dogs (D1, D2, and D3) were coinjected with the canine factor 
IX (cFIX) transposon donor vector and the transposase delivery 
vector at a 2:1 ratio. Virus injections, the viral dose, and the vector 
combinations, which were used in hemophilia B dogs, are sum-
marized in Table 1. D1 received a total dose of 9.4 × 1011 vps/kg of 
the HSB5 system and D2 a 2.6-fold increased dose (2.4 × 1012 vps/
kg). As a control, dog D3 was injected with the inactive version of 
the transposase system at a total dose of 1.2 × 1012 vps/kg, which 
was equivalent to the virus dose applied in dog D1.
For dog D1, which received the HSB5-based hybrid-vector 
system, the whole blood clotting time was shortened to 18.5 min-
utes and stabilized for the total length of the study (960 days) 
(Figure 3a). This clearly demonstrated that phenotypic correction 
of the coagulation factor IX deficiency occurred and suggested 
that in contrast to our historical study utilizing a comparable dose 
of the cFIX encoding vector,25 stabilization of transgene expres-
sion occurred. In sharp contrast, systemic administration of the 
inactive transposase system (mSB) in dog D3 at a similar viral 
dose resulted in transient phenotypic correction for <16 days 
(Figure 3c). Surprisingly, dog D2, which also was treated with the 
HSB5-system but with an increased dose showed only transient 
phenotypic correction (Figure 3b). This may indicate that toxic 
side effects associated with the incoming viral proteins or a robust 
immunological response against incoming vps or against one of 
the transgene products may have occurred.
In order to monitor transgene expression, cFIX levels in 
canine plasma samples were monitored. We detected supra-
physiological plasma cFIX levels of up to 40,000 ng/ml (normal 
table 1 summary of animal injections
Animal species Gender Weight
Vector 1 Vector 2
type tu/kg vps/kg type tu/kg vps/kg
M1 C57Bl/6 mouse Female ~25 g HC-AdV-TcFIX 6.0 × 1010 1.2 × 1012 HC-AdV-HSB5 2.0 × 1010 4.0 × 1011
M2–M4 C57Bl/6 mice Female ~25 g HC-AdV-TcFIX 6.0 × 1010 1.2 × 1012 HC-AdV-mSB 2.0 × 1010 4.0 × 1011
M5–M6 C57Bl/6 mice Female ~25 g HC-AdV-TcFIX 1.2 × 1011 2.4 × 1012 HC-AdV-HSB5 4.0 × 1010 8.0 × 1011
M7–M8 C57Bl/6 mice Female ~25 g HC-AdV-TcFIX 1.2 × 1011 2.4 × 1012 HC-AdV-mSB 4.0 × 1010 8.0 × 1011
D1 Hemophilia B dog Female 16.3 kg HC-AdV-TcFIX 3.1 × 1010 6.2 × 1011 HC-AdV-HSB5 1.6 × 1010 3.2 × 1011
D2 Hemophilia B dog Female 13.7 kg HC-AdV-TcFIX 7.7 × 1010 1.5 × 1012 HC-AdV-HSB5 3.9 × 1010 7.8 × 1011
D3 Hemophilia B dog Female 16.7 kg HC-AdV-TcFIX 3.4 × 1010 7.0 × 1011 HC-AdV-mSB 1.7 × 1010 3.4 × 1011
Abbreviations: HC-AdV, high-capacity adenoviral vector; HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive transposase system; TU, transducing units; 
vps, viral particles.
Mice (M1–M8) and hemophilia B dogs (D1–D3) were injected either with the hyperactive (M1, M5, M6, D2) or the inactive SB (M2–M4, M7, M8, D3) Sleeping Beauty 
(SB) transposase system. For injections into mice, two independent experiments are shown (M1–M4 and M5–M8).
Molecular Therapy  vol. 18 no. 11 nov. 2010 1899
© The American Society of Gene & Cell Therapy













































No CCI4 treatment 
113% 
(n = 3) 
86% 
(n = 5) 
8% 
(n = 5) 
14% 












































Figure 2 stability of expression levels in mice treated with 
 adenovirus-transposase hybrid-vectors and acute toxicity related 
with vectors. C57Bl/6 mice were coinjected with HC-AdV-TcFIX and 
HC-AdV-HSB5 at a ratio of 3:1 with a total number of 8 × 1010 viral par-
ticles (mouse M1) or 4 × 1010 viral particles (mice M5 and M6). Mice of 
the control groups were treated with HC-AdV-mSB instead of HC-AdV-
HSB5 (8 × 1010 viral particles: mice M2–M4; 4 × 1010 viral particles: mice 
M7 and M8). Four to seven weeks after vector administration rapid hepa-
tocyte proliferation was induced at day 0 by intraperitonal injection of 
carbon tetrachloride (CCl4) to analyze stability of transgene expression 
and somatic integration. (a) Canine FIX expression levels were measured 
periodically by ELISA. (b) Relative transgene expression levels in mice 
after delivery of HC-AdV-TcFIX with either HC-AdV-HSB5 (TcFIX/HSB5 + 
CCl4), HC-AdV-mSB (TcFIX/mSB + CCl4) or the irrelevant vector HC-AdV-
luciferase (TcFIX/Luc + CCl4) as a control for persistence of the canine 
FIX-expressing vector without excision of the transgene by Flp recom-
bination. To analyze persistence of transgene expression without CCl4 
treatment (TcFIX/luc −CCl4), another control group solely received the 
vector HC-AdV-TcFIX and HC-AdV-luciferase. A total of 8 × 108 transduc-
ing units were injected at a ratio of 3:1 (transposon TcFIX vector: HSB5, 
mSB, or Luc vector). Mice were treated with CCl4 and serum levels of cFIX 
before CCl4 treatment (white bar) were defined as 100% for each group. 
Black bar, post-CCl4 treatment; gray bar: no CCl4 treatment. Serum cFIX 
levels were determined 3 weeks after CCl4 treatment for all groups. 
(c) Alanine transaminase (ALT) levels in serum samples of mice 1 day 
postinjection were measured to detect acute liver toxicity related with 
HC-AdV administration. Serum samples of mice injected with Dulbecco’s 
phosphate-buffered saline (DPBS), the solvent for intravenous application 
of HC-AdVs were used as a negative control. cFIX, canine factor IX; ELISA, 
enzyme-linked immunosorbent assay; HC-AdV, high-capacity adenoviral 
vector; HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive 
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Figure 1 Mechanism of sleeping Beauty (sB) transposition and 
the high-capacity adenoviral vector (Hc-AdV) system for deliv-
ery. (a) Depicted is a two-component system in which a gene of 
 interest flanked by transposon-derived inverted repeats (IRs) is mobi-
lized by the transposase protein provided in trans. For gene transfer 
experiments, the transposon is usually excised from a plasmid and 
integrated into a genomic target site (TA). This mechanism is com-
monly referred to as “cut-and-paste” mechanism. (b) HC-AdV-TcFIX 
represents the transposon-donor vector from which the transposon is 
mobilized. The transposon15 flanked by inverted repeats (IRs) and FRT 
sites for Flp-mediated excision. It expresses canine coagulation factor 
IX (cFIX) under control of the liver-specific human α-1-antitrypsin pro-
moter (hAAT) including two liver-specific enhancers (HCR, hepatocyte 
control region; ApoE: apolipoprotein E). The HC-AdV-HSB5 contains 
a transgene expression-cassette for the hyperactive Sleeping Beauty 
(SB) transposase HSB5 under the control of the phosphoglycerate 
kinase promoter (PGK) and an expression-cassette for the Flp recombi-
nase driven by the elongation factor-1-α promoter (EF1α). The control 
vector HC-AdV-mSB contains the mutated and inactive version of SB 
(mSB). All HC-AdVs include 22-kb stuffer DNA derived from human 
chromosomal DNA to optimize packaging of viral vectors. (c) For 
somatic integration cells are simultaneously infected with HC-AdV-
TcFIX and HC-AdV-HSB5. Expressed Flp-recombinase recognizes FRT 
sites and mediates circularization and therefore transposon mobi-
lization from the HC-AdV, which is essential for HSB5 functionality. 
Inverted repeats (IRs) of circularized intermediates are recognized by 
expressed hyperactive SB protein provided in trans, mediating somatic 
integration of the transposon into the cellular genome. HC-AdV, high-
capacity adenoviral vector; HSB5, hyperactive Sleeping Beauty trans-
posase; mSB, inactive transposase system.
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cFIX level = 5,000 ng/ml) for dog D1 3–9 days postinjection 
(Figure 4a). During days 9 and 27 postinjection, we observed 
a rapid decline of cFIX plasma levels. However, after 4 weeks, 
plasma cFIX levels stabilized within a therapeutic range 
(60 ng/ ml) for up to 295 days (latest time point analyzed by 
cFIX ELISA). For dogs D2 and D3 we observed physiological 
cFIX plasma levels 5–10 days postinjection which declined to 
undetectable levels 40 and 20 days postinjection for dogs D2 and 
D3, respectively (Figure 4b,c).
laboratory measurements and toxicity profile 
in hemophilia B dogs
To investigate whether vector related toxicity occurred, we per-
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Figure 3 Whole blood clotting time (WBct) as indicator for phenotypic correction in treated hemophilia B dogs. The whole blood clotting time 
(WBCT) is an indicator for a functional coagulation cascade and therefore for a sufficient replacement of the inactive factor IX in hemophilia B dogs. 
The WBCT for untreated hemophilia B dogs is longer than 60 minutes. After injection of HC-AdVs the WBCT was measured periodically for (a) D1 
(HSB5/low dose), (b) D2 (HSB5/high dose), and (c) D3 (mSB). The black arrow indicates a bleeding episode, which was treated by cFIX administration. 
cFIX, canine factor IX; HC-AdV, high-capacity adenoviral vector; HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive transposase system.
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Figure 4 expression levels of canine factor IX in treated hemophilia B dogs. The expression level of canine factor IX (cFIX), which is encoded by 
the transposon, was measured by ELISA. Normal cFIX plasma levels of healthy dogs are between 500 and 12,000 ng/ml. Notably, 50 ng/ml are suf-
ficient for effective coagulation (therapeutic level). Plasma levels of cFIX were measured in hemophilia B dog (a) D1 (HSB5/low dose), (b) D2 (HSB5/
high dose), and (c) D3 (mSB). The black arrow indicates the administration of cFIX after a bleeding episode. ELISA, enzyme-linked immunosorbent 
assay; HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive transposase system.
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aspartate aminotransferase (normal range, 12–118 U/l) and ALT 
(normal range, 15–66 U/l) levels in plasma of dogs D1, D2, and 
D3. We found that ALT and aspartate aminotransferase levels 
were elevated in dog D2, whereas transaminase levels for dogs D1 
and D3 remained in a normal range (Figure 5a,b). Quantification 
of alkaline phosphatase levels revealed that this parameter was 
increased in dog D2, whereas levels stayed in a normal range for 
dogs D1 and D3 (Figure 5c). In concordance with these results, 
we also observed the most significant drop of platelets in dog 
D2 (Figure 5d). Furthermore, all other monitored parameters 
remained in a normal range for dogs D1 and D3. All laboratory 
measurements for treated dogs D1, D2, and D3 are summarized in 
Supplementary Table S1.
lack of antibodies against cFIX and detection of low 
levels for neutralizing antiadenoviral antibodies
To further investigate the potential reasons for transient pheno-
typic correction in dogs D2 and D3 and the rapid decrease of 
cFIX plasma levels in dog D1 during the first weeks postinjec-
tion, we searched for anti-cFIX inhibitors and measured neutral-
izing antiadenoviral antibody levels. The Bethesda inhibitor assay 
was used to detect anti-cFIX inhibitors in dog plasma before and 
after injection, but no antibodies against the transgene-encoded 
product were detected in either dog (data not shown). Thus, 
the decrease in cFIX transgene expression was not caused by a 
humoral immune response directed against the recombinant 
cFIX protein.
For analysis of the humoral immune response directed against 
the adenoviral vector, we examined dog serum at various time 
points for the presence of antiadenoviral neutralizing antibodies. 
For this purpose, we used a neutralization assay, measuring the 
inhibitory effect of antiadenoviral antibodies contained in canine 
serum samples by infection of 293 cells with an adenoviral vec-
tor encoding a reporter gene. Neutralizing antibodies for dog D1 
were monitored until the end of the experiment (960 days postin-
jection) and for dogs D2 and D3 up to 80 days postinjection (latest 
time points measured). Highest levels were measured 2–3 weeks 
post-treatment (Figure 6). Although the biological relevance of 
this finding is not clear at the time, injection of HC-AdVs at a sim-
ilar dose resulted in comparable or even higher levels of neutral-
izing antibodies in a previous study,25 indicating that these  levels 
are normal for the injected vector dose.
Molecular analysis of transgene persistence and 
detection of transposition events in canine liver
To demonstrate that the cFIX transposon underwent transposi-
tion in canine liver and to analyze the fate of transduced vector 
DNA, we performed detailed molecular analyses of liver-derived 
canine genomic DNA. First, we addressed the question whether 
episomal vector forms were maintained in liver cells or whether 
they were lost over time. Therefore, we performed semiquantitative 
PCR analysis of liver genomic DNA isolated from dog D1 960 days 
postinjection specifically detecting vector genome sequences con-

















−1 0 1 2 3 4 15 
Time (days) 
D1 (HSB5/low dose) 
D2 (HSB5/high dose) 
D3 (mSB) 
c 
−1 0 1 2 3 4 15 
Time (days) 
D1 (HSB5/low dose) 





















−1 0 1 2 3 4 
Time (days) 
D1 (HSB5/low dose) 


























−1 0 1 2 3 4 
Time (days) 
D1 (HSB5/low dose) 



















Figure 5 Acute toxicity profile of treated hemophilia B dogs. Plasma samples of dogs D1 (HSB5/low dose), D2 (HSB5/high dose), and D3 (mSB) 
were collected at indicated time points and analyzed for markers related with acute liver toxicity. (a) Alanine aminotransferase levels (ALT; normal 
range 12–118 U/l) were measured as well as (b) aspartate aminotransferase levels (AST; normal range 15–66 U/l), and (c) alkaline phosphatase levels 
(normal range 5–131 U/l). In addition (d) the number of platelets (normal range 200,000–500,000 per mm3) were quantified for all three dogs. 
HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive transposase system.
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in Supplementary Figure S2). We observed that episomal vector 
forms either containing the cFIX transposon (HC-AdV-TcFIX and 
the excised circular cFIX transposase substrate) or the hyperactive 
transposase (HC-AdV-HSB5) were below 0.01 and 0.0002 genome 
copy numbers per cell, respectively (Figure 7a). These results indi-
cated that episomal vector genome numbers were strongly reduced 
over time. In contrast, 0.01 copy numbers per cell of the cFIX 
transposon were maintained in canine liver (Figure 7a) suggesting 
that cFIX expression was mainly derived from integrated transpo-
sons. However, more detailed studies need to be performed and 
at the time we cannot exclude whether transgene expression from 
episomal vector genomes may also contribute to measurable cFIX 
expression levels and phenotypic correction in dog D1. Similar 
tendencies for the vector status were obtained in mice (Figure 7a). 
In addition canine genomic DNA was analyzed for excised and 
episomal circular intermediates, but no evidence for the excised 
transposons could be shown (Supplementary Figure S3).
To determine sites of insertion after transposition, we applied 
a PCR-based assay, which detects chromosomal DNA linked to 
the integrated transposon inverted repeats (IRs). We identified 
transposition events with intact IR and integration into a target 
site-dinucleotide in genomic DNA of canine liver cells derived 
from dog D1 (Figure 7b; detailed blast results are depicted in 
Supplementary Figure S4).
dIscussIon
This study evaluated for the first time efficacy of the SB trans-
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Figure 6 neutralizing antibodies directed against adenoviral vectors 
in treated hemophilia B dogs. As an indicator for the adaptive immune 
response challenged by the HC-AdVs, neutralizing antibodies directed 
against the vector were measured. Therefore, the highest dilution of 
canine serum was determined, which is able to inhibit 50% transduc-
tion efficiencies of a reporter virus in 293 cells. The neutralizing-antibody 
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Figure 7 Molecular status of vector genomes and detection of transposition events in transduced liver cells. Hyperactive Sleeping Beauty trans-
posase (HSB5)-transduced liver samples of mouse M1 (28 days post-CCl4 treatment) and dog D1 (960 days postinjection) were analyzed regarding 
episomal HC-AdV genomes and canine factor IX (cFIX) transposon integrated into the host genome. (a) Fate of vector genomes in transduced canine 
and murine liver was analyzed by PCR. Top, total number of coagulation factor IX transgenes; middle, detection of intact and episomal transposase 
donor-vector genomes (high-capacity adenoviral vector HC-AdV-TcFIX); bottom, PCR specifically detecting Sleeping Beauty transposase encoding 
sequences. D1, liver genomic DNA from dog D1 (500 ng); dil. D1, liver genomic DNA from dog D1 (10 ng); M1, liver genomic DNA from mouse 
M1 (10 ng). Serial DNA standard dilutions ranged from 1 ng (10−9 g; 2.2 × 107 genome copies) to 1 fg (10−15 g; 22 genome copies) were analyzed 
and spiked with 50-ng genomic DNA derived from 293 cells to simulate canine genomic DNA in samples. Genomic DNA obtained from HeLa cells, 
infected with the corresponding viral vectors was used as positive control (+) whereas DNA from noninfected HeLa cells served as negative control 
(–). Vector genome copies are presented as copy numbers per liver cell (copy number/cell). (b) Identification of sites of insertion in canine liver cell 
genomes after HSB5-mediated transposition. Genomic regions containing the transposon were isolated, sequenced, and blasted against the canine 
genome database. Five integration events are depicted and the corresponding chromosomal regions are mentioned. HC-AdV, high-capacity adeno-
viral vector.
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transposon-based vector system for somatic integration was 
 delivered into hemophilia B dogs by a HC-AdV. We found that one 
dog (D1) showed long-term phenotypic correction (Figure 3a) of 
the clotting disorder (3 years) and persistent expression of cFIX 
(Figure 4a) which was mainly derived from integrated transgenes 
(Figure 7a). Furthermore, there was no measurable acute liver 
toxicity (Figure 5a–d).
However, application of a twofold higher viral dose (2.4 × 
1012 vps/kg body weight) showed transient albeit complete cor-
rection of the hereditary genetic disease in canines (Figure 3b). 
Therefore, increasing the viral dose resulted in transient liver tox-
icity (Figure 5a–d) and may present one potential reason for the 
strong decrease of plasma cFIX levels observed in dog D2. A similar 
or even higher dose as compared to dog D2 was used in  previous 
studies for phenotypic correction of canine hemophilia.26,36,37 
In concordance with our present study, these studies also mea-
sured transient hepatotoxicity after systemic administration 
of the HC-AdV at a viral vector load of 1–3 × 1012 vps/kg body 
weight. These dose-dependent toxic effects are supported by our 
historical data in hemophilia B dogs showing that a lower dose 
of 0.9 × 1011 vps/kg resulted in undetectable liver  toxicity and no 
thrombocytopenia.25
As speculated already in other studies performed in canines, 
our data emphasize that only a small therapeutic window for 
HC-AdV may exist. This dose threshold effect, for which a lin-
ear increase in viral vector dose does not correlate with protein 
expression, was also shown in mice.38 However, the minimal 
dose in mice for achieving long-term transgene expression seems 
to be lower compared to canines. This underscores the species-
 dependent differences after systemic administration of adenoviral 
vectors and that direct extrapolation across species may not be 
possible.
In the present study, we explored for the first time a hyperactive 
SB transposase for somatic integration from an adenoviral vector. 
We believe that utilizing HSB5 with a tenfold higher transposition 
activity in vitro in comparison to wild-type SB which was used in 
our previous study25 was probably a critical factor for achieving 
stabilized transgene expression in a large animal model. However, 
the actual integration efficiency of the HSB5-based system and the 
grade of improvement in comparison to our previously described 
two-vector system utilizing wild-type SB transposase30 needs to 
be investigated in more detail. To further optimize our integrating 
vector system it may be interesting to explore a novel SB trans-
posase mutant with 100-fold increased integration efficiencies 
(SB100×).39 In fact, utilizing SB100× may allow further decreas-
ing the viral vector dose for achieving sufficient integration and 
stabilized transgene expression, although a minimal dose which 
yet remains to be determined will still be required for cotransduc-
tion of cells with both vectors. Another approach for reducing the 
effective viral vector dose may be the use of hyperactive cFIX vari-
ants as shown by Brunetti-Pierri et al., who delivered a hyperactive 
human FIX expression-cassette using an adenoviral vector result-
ing in an improved therapeutic effect.40 Moreover, with respect to 
targeting liver cells, our approach could be optimized by utilizing 
more efficient routes of administration. For instance, the recently 
introduced pseudo-hydrodynamic balloon catheter injection 
method was shown to increase liver-transduction efficiency.24
Taking a closer look at the antiadenoviral neutralizing-
antibody levels (Figure 6) for all treated dogs, an increase was 
observed 2 weeks after administration. During this time period, 
plasma cFIX levels decreased to low or even undetectable levels 
for all dogs. Because no significant anti-cFIX inhibitor levels were 
detected, this increase in antiadenoviral neutralizing-antibody 
levels could suggest that a robust adaptive immune response 
against the administrated viral vector capsids or cells presenting 
viral capsid proteins occurred. In particular the cellular immune 
response might be one major reason for the subsequent clearance 
of transduced cells and therefore the rapid decline in cFIX anti-
gen levels. However, in the present study, we only analyzed antia-
denoviral neutralizing-antibody levels in hemophilia B dogs and 
it is important to emphasize that not only the humoral immune 
response but also the innate immune system may play an impor-
tant role.
Another safety issue of our hybrid-vector system may be the 
presence of HSB5 and Flp recombinase encoding DNA sequences 
in our vectors. Besides the fact, that for the SB transposase system 
overproduction inhibition could occur, which might potentially 
be the reason for transient effects in dog D2, high levels of SB 
transposase and/or Flp recombinase might result in genotoxicity 
or other adverse effects. Furthermore, at the time it is not known 
whether long-term expression in vivo of either SB transposase 
and/or Flp recombinase causes any side effects such as unwanted 
recombination of host genomic DNA which might even occur at 
low expression rates. However, our results indicated that episomal 
vector genomes were strongly reduced over time or even com-
pletely cleared from the organ. This could be shown for the  vector 
encoding HSB5 as well as for cFIX (Figure 7a). These results are 
in concordance with previous data showing low frequencies of 
adenoviral vectors for homologous or heterologous integration 
events in transduced hepatocytes in mice.28,29
Regarding the safety for SB transposase-mediated integra-
tion, it is established that SB transposase mediates somatic inte-
gration into target site-dinucleotides.31 Up to now no insertional 
mutagenesis is known for gene therapy studies utilizing SB trans-
posases and a recent study revealed that SB shows a random 
integration pattern with a small bias toward genes.41 Moreover, 
integration preferences were not significantly influenced by tran-
scriptional activity. Although the dog-specific genomic sequence 
database from National Center for Biotechnology Information 
(NCBI) is not complete,42,43 we have begun to analyze insertion 
sites after SB-mediated somatic integration from the adenoviral 
vector into the canine genome (Figure 7b). We realize that the 
number of insertion sites my not be representative at this point, 
but our genome-wide screen for sites of transposition events from 
the adenoviral vector in murine liver cells revealed a random inte-
gration pattern without any preferences for integration into tran-
scriptionally active sites (data not shown).
The combination of the SB transposase system with gutless 
adenovirus showed significantly stabilized transgene expression 
during rapid cell cycling (Figure 2a). Furthermore, we showed 
that in the presence of cell division our novel vector system was 
superior to conventionally utilized and episomally maintained 
HC-AdVs (Figure 2b). However, we are aware of the fact that 
hepatocytes are in most cases quiescent cells and therefore, stable 
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liver-transduction for the treatment of hemophilia B may not be 
the perfect setup and model disease for our novel vector system. 
Moreover, it was also demonstrated that a single injection of an 
HC-AdV without integration machinery can result in long-term 
expression and phenotypic correction.16,20–23 However, for instance 
for stable transduction of stem cells, progenitor cells or any other 
cell type which may undergo extensive cell division, our system 
may be a very valuable tool.
It is of note that in a previously published study, we found 
that HC-AdV genomes seem to be more stable during cell divi-
sion compared to nonviral DNA.44 However, within the present 
study we found that after injection of HC-AdV-TcFIX alone and 
subsequent CCl4 treatment for induction of cell cycling transgene 
expression levels rapidly declined. This loss in transgene expres-
sion was as extensive as in mice which received the mSB encod-
ing vector. Although this is somewhat different to our previously 
published study it is important to point out that in contrast to our 
newly performed experiment our previous study utilized partial 
hepatectomy for induction of cell cycling resulting into 2–3 cell 
divisions of each hepatocyte. In contrast, treatment with CCl4 is 
harsher and results into extensive liver necrosis and subsequently 
also more cell divisions. This in turn may lead to a more extensive 
loss of episomal vector genomes. This is on concordance with our 
previous study in which we also observed a dramatic loss of trans-
gene expression and vector genome copies after CCl4 treatment.
45
It is of note, that adenoviral vectors were utilized in the past to 
deliver other than SB-based integration machineries derived from 
retrotransposons, retrovirus, AAV, and bacteriophage-derived 
integrase phiC31 (reviewed in ref. 46). At the time, none of the 
currently available systems for somatic integration may be per-
fect with respect to genotoxicity and SB-mediated integration may 
represent a valuable alternative, however, site-specific integration 
into a single and “safe” genomic locus may be the ideal option. 
Towards this goal, SB fusion proteins exploring zinc-fingers for 
site-specific DNA binding32,45 and zinc-finger nucleases in the 
context of viral vectors46 are currently being explored.
Last but not least, one important challenge which needs to 
be addressed in the future is the complexity of the design of this 
adeno virus/SB transposase hybrid-vector system. To increase 
integration efficiency the ratio between transposons and SB trans-
posase proteins should be optimized including the ratio between 
vectors and the promotors driving the transcription of SB trans-
posase and Flp recombinase. Moreover, utilizing an inducible 
system for expression of the integration machinery might reduce 
genotoxic and immunogenic side effects and may decrease an 
overproduction inhibition effect. Finally, we believe that explor-
ing a “one- vector-strategy” including all components for somatic 
 integration (therapeutic DNA and the respective recombinase) 
in one vector genome is an option to overcome the necessity of 
cotransduction of one cell with two vectors.
In summary, this study provides for the first time novel insights 
into efficacy of adenoviral hybrid-vectors for somatic integration 
and the SB system in a larger animal model. For stable transduc-
tion and treatment of tissues with a high-cell turn-over rate, our 
system represents a valuable tool for treatment. For instance, 
treatment of diseases affecting the skin or ex vivo correction of 
hematopoietic stem cells may be feasible utilizing our vector 
system. We believe that with further improvements this system 
may even pave the way toward clinical applications.
MAterIAls And MetHods
Generation of HC-AdVs. See Supplementary Materials and Methods 
section for detailed description of cloning procedures for generation of 
adenoviral production plasmids and HC-AdV amplification, purification, 
and titration.
Animal studies. C57Bl/6 mice were kept and treated according to the guide-
lines of the Ludwig Maximilians University of Munich (Munich, Germany). 
All mice were tail vein injected using a total volume of 200 μl. Viral vector 
preparations were diluted in Dulbecco’s PBS. Rapid cell cycling of murine 
liver cells was induced by intraperitoneal administration of 50 μl CCl4 (Sigma-
Aldrich, Taufkirchen, Germany) solution (1:1 dilution in mineral oil).
Inbred hemophilia B dogs were from the University of North Carolina 
at Chapel Hill (Chapel Hill, NC). These hemophilia B dogs carry a missense 
mutation in the catalytic domain of the FIX-coding sequence resulting 
in undetectable FIX activity.35 Dog studies were performed under the 
guidelines of the University of North Carolina. For vector administration, 
dogs were sedated with Domitor (750 μg/m2 body surface area) and 
the vector dilution (~18.5 ml) followed by ~10 ml PBS for vector wash 
was infused by peripheral vein injection at 0.5 ml/minute into the right 
foreleg. During injection heart rate, blood pressure, and temperature were 
monitored. Routine laboratory measurements before and after adenoviral 
administration were performed as described earlier.25,47
Measurement of ALT serum levels in mice. For quantification of ALT levels 
in murine serum, we followed the instructions of the ALT detection kit 
(Randox, Crumlin, UK) as described earlier.45 We applied 15 μl of murine 
serum for each reaction.
Blood analysis after adenoviral-mediated gene transfer into hemophilia B 
dogs. Blood samples were obtained periodically from hemophilia B dogs and 
the whole blood clotting time was determined as previously described.25,47 
A Bethesda inhibitor assay was used to detect anti-canine FIX inhibitors in 
dog serum. In brief, dog plasma samples were mixed with pooled normal 
canine plasma and incubated at 37 °C. The anti-canine FIX inhibitor titer 
was calculated from the residual FIX activity of each sample.
ELISA. The cFIX ELISA measuring cFIX levels in murine serum and canine 
plasma was performed.48 Briefly, to coat ELISA plates, the polyclonal  rabbit 
anti-cFIX primary antibody (RACIX-IG; Affinity Biologicals, Ancaster, 
ON, Canada) was diluted 1:500 for dog and 1:200 for mouse samples. After 
incubation with samples obtained from treated animals the sheep horse-
radish peroxidase– conjugated secondary antibody (SACIX-HRP; Affinity 
Biologicals) was diluted 1:1,000 and 1:200 for mouse and canine samples, 
respectively. For generation of a standard curve, dilutions of pooled dog 
plasma with a  normal range of 5–11.5 μg/ml cFIX antigen were used.
Detection of neutralizing antiadenoviral antibodies. The principle of this 
test was to analyze at which dilution the canine serum potentially con-
taining antiadenoviral antibodies is able to inhibit 50% of the  transduction 
of a reporter virus. Two hundred and ninety three cells were cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine 
serum. One day before performing the assay, 293 cells were seeded into 
96-well tissue culture plates containing 100 μl medium. To destroy heat-
sensitive complement components, dog serum was incubated at 56 °C for 
40 minutes. Serum samples were diluted in twofold steps in Dulbecco’s 
modified Eagle’s medium with 10% heat-inactivated fetal bovine serum 
in a total volume of 50 μl. We added 50 μl of the lacZ-expressing reporter 
virus Ad-RSV/lacZ6 diluted with Dulbecco’s modified Eagle’s medium 
containing 10% heat-inactivated fetal bovine serum (final concentration 
of 1 × 109 plaque-forming units/ml). After incubation of 1 hour at 37 °C, 
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the serum-virus mixture was applied to 293 cells with 80%  confluency. 
After 24 hours, cells were fixed with 0.5% glutaraldehyde, washed with 
PBS, and stained in PBS-containing 3 mmol/l potassium ferricyanide, 
3 mmol/l potassium ferrocyanide, 2 mmol/l MgCl2, and 1 mg/ml 5-bromo-
4-chloro-3-indolyl-β-d-galactopyranoside (X-gal). As a negative control 
serum samples derived from untreated dogs and PBS were used. The neu-
tralizing antiadenovirus antibody titer was defined as the reciprocal of the 
highest dilution of serum at which the infectivity of the reporter virus was 
decreased by 50%.
Molecular characterization of vector genomes by PCR. To analyze 
whether adenoviral vector genomes were maintained in murine and 
canine liver and to determine the amount of the integrated cFIX encoding 
transposons, we isolated genomic DNA from liver tissue (~100 mg). PCR 
analysis was performed using GoTaq polymerase (Promega, Mannheim, 
Germany). For mouse samples 10 ng and for canine samples 500 and 10 ng 
(dil. D1) of isolated genomic DNA were subjected to PCR.
Semiquantitative PCRs for detection of total number of canine 
coagulation factor IX (cFIX) encoding DNA were run with 45 cycles at 
95 °C for 45 seconds, 53 °C for 45 seconds, and 72 °C for 60 seconds using 
oligonucleotides ApoE for (5′- CCC AGA GAC TGT CTG ACT CA -3′) 
and cFIXshort.rev (5′-GAG ACA CAC CTC ATT ACA TA-3′). This PCR 
amplifies a 998-bp DNA fragment spanning the liver-specific hAAT 
promoter and the first part of the cFIX complementary DNA. Therefore, 
it detects episomal versions of the cFIX transgene (excised circles after 
Flp-recombinase recombination and complete adenoviral vector genomes 
of HC-AdV-TcFIX) as well as integrated copies of the cFIX encoding 
transposon.
To address the question whether episomal HC-AdV-TcFIX genomes 
(Figure 2b) were present, a touchdown-PCR specific for a 1,455-bp 
fragment of HC-AdV-TcFIX was run with 35 cycles at 95 °C for 45 seconds, 
65 °C for 45 seconds, 72 °C for 90 seconds, decreasing the annealing 
temperature each cycle for 0.3 °C and utilizing the oligonucleotides pICeu 
(5′-TAA CTA TAA CGG TCC TAA GGT AGC -3′) and pApoE/hAAT-3 
(5′- AGA TCA GGG GGA TCA TTC ACT GTC CCA GGT CA-3′).
For detection of HC-AdV-HSB5 a touchdown-PCR was performed 
with 35 cycles at 95 °C for 45 seconds, 65 °C for 45 seconds, 72 °C for 
80 seconds, decreasing the annealing temperature at each cycle for 0.3 °C 
and using the oligonucleotides PGK-Pro_5_ BglII (5′- AGA TCT ACC 
GGG TAG GGG AGG CGC-3′) and HSB5’1,000 (5′-GCT CCC AAG 
GAT GAA CCA GAC TTG-3′) amplifying a 585 bp region.
Circular intermediates were detected by touchdown-PCR (product: 
700 bp). Thirty-five cycles at 95 °C for 45 seconds, 65 °C for 45 seconds, 
72 °C for 50 seconds, decreasing annealing temperature each cycle for 
0.3 °C were performed and the oligonucleotides fwFRTcyclization (5′-
CCA AGC TGT TTA AAG GCA CA-3′) and rev1FRTcyclization (5′-GTA 
GGT CAC GGT CTC GAA GC-3′) were used.
For calculation of genome copy numbers per cell we performed serial 
DNA standard dilutions of plasmids pHC-AdV-TcFIX and pHC-AdV-
HSB5 ranging from 1 ng (10−9 g; 2.2 × 107 copies) to 1 fg (10−15 g; 22 copies). 
Dilutions were spiked with genomic DNA derived from HeLa cells. For 
calculation of genome copy numbers per cell, we took into account that 
one copy of a diploid canine and mouse genome contains 5 billion and 
5.7 billion bp, respectively.
Analysis of sites of insertion after transposon-mediated somatic integra-
tion in canine liver cells. Genomic DNA isolated from canine liver cells was 
used to determine sites of insertion by the BD GenomeWalkerTM Kit from 
BD Biosciences Clontech (Heidelberg, Germany). Therefore four genomic 
DNA libraries were produced with restriction enzyme nucleases that create 
blunt-ended DNA fragments (StuI, EcoRV, PvuII, and SspI) and a linker was 
ligated to the DNA fragments. Subsequently a two-step PCR was performed 
in which one primer binds to the IR of the IR and the other primer binds 
to the linker (primer pair for first PCR: IR-specific primer 1, 5′-cct taa gac 
agg gaa tct tta ctc gga-3′ and adopter primer 1, 5′-gta ata cga ctc act ata ggg 
c-3′; primer pair for the nested PCR: IR-specific primer 2, 5′-ggc taa ggt gta 
tgt aaa ctt ccg act -3′ and adopter primer 2, 5′-act ata ggg cac gcg tgg t-3′). 
PCR products were subcloned using the Zero Blunt TOPO PCR cloning kit 
(Invitrogen, Karlsruhe, Germany) and analyzed by sequencing. Sequencing 
results were blasted against a dog-specific genomic sequence data base from 
NCBI (http://www.ncbi.nlm.nih.gov/projects/genome/guide/dog/).
suPPleMentArY MAterIAl
Figure S1. Expression levels from episomal HC-AdVs.
Figure S2. PCR setups for specific detection of total cFIX and epi-
somal HC-AdVs.
Figure S3. Detection of circular intermediates in transduced canine 
liver cells.
Figure S4. Detailed description of integration sites after SB-mediated 
transposition into genomic DNA of canine liver cells.
Table S1. Laboratory measurements of dogs D1 (HSB5), D2 (HSB5, 
high dose), and D3 (mSB).
Materials and Methods.
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